MarketCap
Facebook
X
TelegramAnnual report 2023
added 03-05-2024
Nektar Therapeutics Market Cap 2011-2025 | NKTR
As of December 05, 2025 Nektar Therapeutics has a market cap of $ 10.8 B
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Nektar Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 167 M | 260 M | 2.04 B | 3.52 B | 3.55 B | 7.31 B | 12.9 B | 1.64 B | 1.81 B | 1.86 B | 1.62 B | 976 M | 721 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 12.9 B | 167 M | 2.95 B |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AbCellera Biologics
ABCL
|
859 M | $ 3.56 | -2.47 % | $ 1.05 B |  Canada |
 |
AC Immune SA
ACIU
|
305 M | $ 2.81 | -2.43 % | $ 229 M |  Schweiz |
 |
ADiTx Therapeutics
ADTX
|
59.2 K | $ 2.99 | 2.75 % | $ 39.4 K |  USA |
 |
Aeterna Zentaris
AEZS
|
41.4 M | - | 5.93 % | $ 314 M | Canada |
 |
Abeona Therapeutics
ABEO
|
149 M | $ 4.81 | -1.33 % | $ 103 M | USA |
 |
ARCA biopharma
ABIO
|
484 M | - | 1052.0 % | $ 415 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
32.8 M | - | - | $ 26.5 M | USA |
 |
Akouos
AKUS
|
172 M | - | 0.23 % | $ 488 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
1.83 B | $ 11.96 | 0.17 % | $ 3.7 B | USA |
 |
Axcella Health
AXLA
|
25 M | - | -16.42 % | $ 249 M | USA |
 |
Acer Therapeutics
ACER
|
12.1 M | - | 2.71 % | $ 14 M | USA |
 |
Atreca
BCEL
|
49 M | - | -11.76 % | $ 5.79 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
6.33 M | - | -2.5 % | $ 5.88 M | USA |
 |
argenx SE
ARGX
|
13.8 B | $ 898.63 | -1.89 % | $ 25 B |  Niderland |
 |
Armata Pharmaceuticals
ARMP
|
133 M | $ 5.91 | 1.55 % | $ 213 M | USA |
 |
Achieve Life Sciences
ACHV
|
90.2 M | $ 4.68 | -2.2 % | $ 92.8 M | USA |
 |
BioDelivery Sciences International
BDSI
|
308 M | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
253 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Acorda Therapeutics
ACOR
|
16.7 M | - | -24.86 % | $ 820 K | USA |
 |
Ascendis Pharma A/S
ASND
|
7.37 B | $ 205.89 | -1.29 % | $ 5 B |  Danmark |
 |
Alterity Therapeutics Limited
ATHE
|
895 M | $ 3.48 | 1.45 % | $ 8.37 B |  Australia |
 |
Acasti Pharma
ACST
|
40.7 M | - | 4.01 % | $ 150 M | Canada |
 |
Bellerophon Therapeutics
BLPH
|
78.6 M | - | -74.18 % | $ 955 K | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
2.05 B | - | -15.15 % | $ 60.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B | USA |
 |
Baudax Bio
BXRX
|
779 K | - | 0.59 % | $ 63 K | USA |
 |
AbbVie
ABBV
|
342 B | $ 225.34 | -1.46 % | $ 399 B | USA |
 |
Cara Therapeutics
CARA
|
54.1 M | - | -3.03 % | $ 260 M | USA |
 |
CymaBay Therapeutics
CBAY
|
3.43 B | - | - | $ 3.45 B | USA |
 |
BioLineRx Ltd.
BLRX
|
1.35 B | $ 3.29 | 0.95 % | $ 908 M |  Israel |
 |
ChemoCentryx
CCXI
|
1.82 M | - | - | $ 3.74 B | USA |
 |
Codiak BioSciences
CDAK
|
240 M | - | -55.98 % | $ 2.15 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
1.18 B | $ 15.35 | -12.11 % | $ 2.26 B | USA |
 |
Avid Bioservices
CDMO
|
423 M | - | - | $ 789 M | USA |
 |
Biogen
BIIB
|
19.3 B | $ 182.33 | 0.19 % | $ 26.5 B | USA |
 |
Cerevel Therapeutics Holdings
CERE
|
6.68 B | - | - | $ 7.29 B | USA |
 |
ContraFect Corporation
CFRX
|
1.08 M | - | -5.16 % | $ 5.39 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | USA |
 |
Beam Therapeutics
BEAM
|
2.5 B | $ 27.55 | -4.72 % | $ 2.27 B | USA |
 |
BioMarin Pharmaceutical
BMRN
|
13.1 B | $ 53.06 | -1.41 % | $ 10.1 B | USA |
 |
BioNTech SE
BNTX
|
62.9 B | $ 96.0 | - | $ 27.2 B |  Germany |
 |
Clearside Biomedical
CLSD
|
101 M | - | - | $ 25.3 M | USA |
 |
Celsion Corporation
CLSN
|
21.1 M | - | -6.63 % | $ 13.9 M | USA |
 |
Clovis Oncology
CLVS
|
231 M | - | -7.23 % | $ 13 M | USA |
 |
Advaxis
ADXS
|
1.87 M | - | -9.65 % | $ 45.9 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
52.7 M | - | - | $ 231 M | USA |
 |
Chimerix
CMRX
|
104 M | - | - | $ 756 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
103 M | - | - | $ 401 M | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
8.59 B | $ 9.36 | -2.65 % | $ 605 M | USA |
 |
AgeX Therapeutics
AGE
|
14.1 K | - | -10.17 % | $ 12.2 K | USA |